A Phase II, Open-Label, Randomized Study to Compare the Efficacy and Safety of EPIVIR/ZIAGEN/Zerit (3TC/ABC/d4T) Versus EPIVIR/ZIAGEN/Sustiva (3TC/ABC/EFV) Versus EPIVIR/ZIAGEN/GW433908/Norvir (3TC/ABC/908/RTV) for 96 Weeks in the Treatment of HIV-1 Infected Subjects Who are Antiretroviral Thera ...
Infection, Human Immunodeficiency Virus I
Phase 2
A link to and a NCT ID number is not available for this study because the study was conducted before regulatory requirements to register studies. Due to the age of this study, the analysis-ready dataset and dataset specification are not available.
April 2014